Skip to content
Agree.net – Lifestyle
Author:
Lexeo Therapeutics
Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November
November 2, 2026
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
October 19, 2026
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
October 8, 2026
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
October 1, 2026
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
September 23, 2026
Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia
September 22, 2026
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
September 2, 2026
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
August 12, 2026
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
August 5, 2026
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
June 17, 2026
1
2
Next Page
→